ResearchSafe

FDA panel votes on loosening rules for 7 peptides, here's what's actually on the list

Posted by weekendnate in Research & News - 3 points, 4 comments.

https://www.theatlantic.com/health/2026/07/peptide-bpc157-fda-compounding-pharmacy/688052/

The NPR piece covers the FDA advisory committee vote on whether to ease restrictions on seven peptides that a lot of people in this space are already using through compounding. It's worth reading because the list itself tells you which compounds the panel thinks have enough evidence to even be considered, and a couple of the omissions are just as interesting as what made the cut.

My take is that this is overdue. The current situation where everyone is sourcing from random online vendors with zero quality control is the actual safety problem, not the peptides themselves. If a legit pharmacy can compound something under proper oversight, that beats me trusting a vial with a scribbled COA from a Telegram group. I'm skeptical it will move the needle on access soon though. The panel can recommend, but the FDA moving on compounding rules is a separate, slower fight. Curious which of the seven people here are most watching and why.

Comments

  • patient_codes: This is the right direction honestly. The gray market stuff is where the actual risk lives, not the molecules themselves, so tighter oversight can only help. I'm mostly watching BPC-157 and tirzepatide on that list, BPC because the anecdotal recovery stories in this community are everywhere and tirz because access has been a mess for people who legitimately need it. The omissions are loud too, semaglotide being kind of half in half out feels political. My worry is the compounding fight drags on
  • rachel_ketogen: The timeline worry is valid but I think the compounding angle is where pressure actually works. FDA cant make pharmacies stop making sterile compounds if doctors are writing for them. BPC-157 though, Id want to see more than anecdotes before putting it on any official list, but thats just me.
  • weekendnate: You make a fair point about the compounding pressure side, doctors writing the scripts is kind of the lever if this drags. On BPC though, I hear you, and that was honestly my hesitation too. I'm less sold on it than I used to be. The tendon repair stuff in animals looked promising but the human data is basically nothing, and I've seen enough people stack it for months with nothing to show that I'm side-eyeing the whole "miracle peptide" reputation. Curious if you've actually tried it yourself o
  • weekendnate: Yeah, the timeline is the part that bugs me too. The panel can recommend, and then it still has to clear the actual rulemaking process, which from what I've seen on other things takes years. So realistically people keep doing what they're doing for a while regardless. Tirzepatide being on the list but sema in some weird limbo is the most interesting move to me. I read it as the panel basically saying the newer GLP-1 has cleaner data, which if true would be a big deal for anyone thinking about s

Community discussion - research and educational context only. Not medical advice.